budesonide + tiotropium

Budesonide + tiotropium is a combination of two inhaled medications used primarily in the management of chronic obstructive pulmonary disease (COPD). Budesonide is an inhaled corticosteroid that exerts potent local anti-inflammatory effects by inhibiting the production and activity of inflammatory mediators and cells, thereby reducing airway inflammation and preventing airway remodeling. Tiotropium is a long-acting anticholinergic (muscarinic receptor antagonist) that induces bronchodilation by blocking muscarinic M3 receptors on airway smooth muscle, leading to sustained relaxation of bronchial muscles. The combination aims to improve lung function, exercise capacity, symptoms, and quality of life in patients with COPD compared to monotherapy with either agent alone[1][2]. Clinical studies have shown that this combination can lead to significant improvements in health status scores (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume in 1 second (FEV1), and reduction in severe exacerbations[1][2]. Adverse events are generally similar between groups treated with the combination or monotherapy.

Other names

tiotropium/budesonidetiotropium plus budesonidetiotropium and budesonide